Takashi Yamanaka

Long-term Clinical Outcomes of Radiofrequency Ablation for Pathologically Diagnosed T1a Renal Cell Carcinoma: A 10-Year Single-center Experience

Masashi Fujimori, Takashi Yamanaka, Naritaka Matsushita, Seiya Kishi et autres

jp (code pays fourni par la source)

Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE

Tatsunori Shimoi, Nobuhiro Shibata, Masahiro Kitada, Michiko Tsuneizumi et autres

jp, us (code pays fourni par la source)

Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer

Shu Yazaki, Rui Kitadai, Yukihide Momozawa, Teruhiko Yoshida et autres

jp, gb (code pays fourni par la source)

Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study

Hitomi Sakai, Junji Tsurutani, Yukinori Ozaki, Hiroshi Ishiguro et autres

jp, de (code pays fourni par la source)

565P Genomic landscape of triple-negative invasive lobular carcinoma: A distinct subtype revealed in a nationwide multicenter cohort

Mai Hoshino, T. Shimoi, Y Yamaguchi, Toru Imai et autres

jp, us (code pays fourni par la source)

Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study

Kazuki Nozawa, Hiroji Iwata, Toru Mukohara, Thaise Mayumi Taira et autres

jp (code pays fourni par la source)

Abstract P5-03-04: The effectiveness of post-T-DXd treatments in patients with HER2-positive metastatic breast cancer: A nationwide Japanese cohort study (EN-SEMBLE)

Kazuki Nozawa, Hiroji Iwata, Toru Mukohara, Tetsuhiko Taira et autres

Abstract P5-10-05: Differences in drug efficacy between primary and metastatic sites and their prognosis for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, Takashi Yamanaka et autres

Abstract P4-07-19: Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial

Joohyuk Sohn, Kazuki Sudo, Takashi Yamanaka, Hirofumi Mukai et autres

Abstract P4-07-21: Prognostic analysis of operable HR-positive HER2-negative loco-regional recurrent breast cancer; A multi-institutional Retrospective Cohort Study

Emi Tokuda, Yukinori Ozaki, Fumikata Hara, Shinsuke Sasada et autres

Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2‐Year Post‐Marketing Surveillance

Yuko Tanabe, Kenichi Inoue, Masato Takahashi, Hirofumi Mukai et autres

jp (code pays fourni par la source)

221P Long-term outcomes of eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer: Results of the randomized JBCRG-22 study

Hiroyuki Yasojima, N Masuda, Hideaki Bando, Takashi Yamanaka et autres

jp (code pays fourni par la source)